Terms: = Ovarian cancer AND CDX2, CDX3, 1045, ENSG00000165556, Q99626 AND Treatment
12 results:
1. Rare occurrence of pseudomyxoma peritonei (PMP) syndrome arising from a malignant transformed ovarian primary mature cystic teratoma treated by cytoreductive surgery and HIPEC: a case report.
Ponzini F; Kowal L; Ghafoor M; Goldberg A; Chan J; Lamm R; Cannaday SM; Richard SD; Nevler A; Lavu H; Bowne WB; Rosenblum NG
World J Surg Oncol; 2022 Mar; 20(1):78. PubMed ID: 35272690
[TBL] [Abstract] [Full Text] [Related]
2. Clinical Approach to Neuroendocrine Neoplasm Associated With ovarian Teratoma.
Opalińska M; Sowa-Staszczak A; Olearska H; Ulatowska-Bialas M; Gilis-Januszewska A; Hubalewska-Dydejczyk A
Front Endocrinol (Lausanne); 2021; 12():770266. PubMed ID: 34917031
[TBL] [Abstract] [Full Text] [Related]
3. Advanced stage primary mucinous ovarian carcinoma. Where do we stand ?
Nasioudis D; Albright BB; Ko EM; Haggerty AF; Giuntoli RL; Burger RA; Morgan MA; Latif NA
Arch Gynecol Obstet; 2020 Apr; 301(4):1047-1054. PubMed ID: 32185553
[TBL] [Abstract] [Full Text] [Related]
4. Nuclear β-catenin and cdx2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.
Wang L; Rambau PF; Kelemen LE; Anglesio MS; Leung S; Talhouk A; Köbel M
Histopathology; 2019 Feb; 74(3):452-462. PubMed ID: 30326146
[TBL] [Abstract] [Full Text] [Related]
5. Alternative Polyadenylation Patterns for Novel Gene Discovery and Classification in cancer.
Begik O; Oyken M; Cinkilli Alican T; Can T; Erson-Bensan AE
Neoplasia; 2017 Jul; 19(7):574-582. PubMed ID: 28624626
[TBL] [Abstract] [Full Text] [Related]
6. Characteristics, treatment and outcomes of women with immature ovarian teratoma, 1998-2012.
Jorge S; Jones NL; Chen L; Hou JY; Tergas AI; Burke WM; Ananth CV; Neugut AI; Herhshman DL; Wright JD
Gynecol Oncol; 2016 Aug; 142(2):261-6. PubMed ID: 27222024
[TBL] [Abstract] [Full Text] [Related]
7. Regulation of multidrug resistance 1 expression by cdx2 in ovarian mucinous adenocarcinoma.
Koh I; Hinoi T; Sentani K; Hirata E; Nosaka S; Niitsu H; Miguchi M; Adachi T; Yasui W; Ohdan H; Kudo Y
Cancer Med; 2016 Jul; 5(7):1546-55. PubMed ID: 27060927
[TBL] [Abstract] [Full Text] [Related]
8. KRAS mutation in adenocarcinoma of the gastrointestinal type arising from a mature cystic teratoma of the ovary.
Li Y; Zhang R; Pan D; Huang B; Weng M; Nie X
J Ovarian Res; 2014 Sep; 7():85. PubMed ID: 25297496
[TBL] [Abstract] [Full Text] [Related]
9. CK7, CK20, cdx2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
Shin JH; Bae JH; Lee A; Jung CK; Yim HW; Park JS; Lee KY
Jpn J Clin Oncol; 2010 Mar; 40(3):208-13. PubMed ID: 19926591
[TBL] [Abstract] [Full Text] [Related]
10. [Immunohistochemical profile of colorectal and ovarian carcinomas--examination with cytokeratin 7, cytokeratin 20, beta catenin and cDX 2].
Porjazova E; Zaprjanov Z; Batashki I; Markova D; Milchev N
Akush Ginekol (Sofiia); 2009; 48(2):7-12. PubMed ID: 20198769
[TBL] [Abstract] [Full Text] [Related]
11. A PCR/restriction digestion assay for the detection of the transcript variants 1 and 2 of POU5F1.
Panagopoulos I; Möller E; Isaksson M; Mertens F
Genes Chromosomes Cancer; 2008 Jun; 47(6):521-9. PubMed ID: 18335506
[TBL] [Abstract] [Full Text] [Related]
12. Utility of CDX-2 in distinguishing between primary and secondary (intestinal) mucinous ovarian carcinoma: an immunohistochemical comparison of 43 cases.
Raspollini MR; Amunni G; Villanucci A; Baroni G; Taddei A; Taddei GL
Appl Immunohistochem Mol Morphol; 2004 Jun; 12(2):127-31. PubMed ID: 15354737
[TBL] [Abstract] [Full Text] [Related]
